This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not include a full text component.

NEW YORK--(BUSINESS WIRE)--Pathway to Cures (P2C) announced today its inaugural investment of $250,000 in Anvesana to develop therapies for treating inheritable blood and bleeding disorders. Pathway ...

NEW YORK--(BUSINESS WIRE)--Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and ...

Pathway to Cures Portfolio Company Spark Biomedical Receives Wellcome Leap Award for Advancements in Women’s Health: Heavy Menstrual Bleeding Pathway to Cures (P2C) congratulates Dr. Navid Khodaparast ...